Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $83.47

Gilead Sciences, Inc. (NASDAQ:GILD) has received a consensus recommendation of “Hold” from the eighteen analysts that are presently covering the firm, MarketBeat.com reports. Twelve analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $83.47.

GILD has been the subject of several analyst reports. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday, April 24th. Wells Fargo & Company decreased their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Barclays decreased their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Finally, Oppenheimer restated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a report on Friday, April 19th.

Gilead Sciences Stock Performance

GILD stock opened at $68.61 on Friday. The business’s fifty day moving average is $65.98 and its 200-day moving average is $72.58. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company has a market cap of $85.48 billion, a P/E ratio of 190.58, a price-to-earnings-growth ratio of 2.93 and a beta of 0.20. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the prior year, the company earned $1.37 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences will post 3.75 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were given a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s payout ratio is 855.56%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Altfest L J & Co. Inc. bought a new position in Gilead Sciences in the fourth quarter valued at approximately $210,000. Federated Hermes Inc. increased its stake in Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after acquiring an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after acquiring an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new position in Gilead Sciences in the fourth quarter valued at approximately $74,000. Finally, Eagle Asset Management Inc. increased its stake in Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after acquiring an additional 60,697 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.